Schizophrenia Clinical Trial
Official title:
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
This placebo-controlled study is designed to evaluate the efficacy of glycine, an agonist of
the glycine-B co-agonist site of the NMDA receptor, on alcohol consumption and craving as
well as negative symptoms in schizophrenia.
Glycine will decrease the rewarding action of ethanol and reduce ethanol consumption. Also,
glycine will improve negative symptoms and cognitive deficits in schizophrenia.
OBJECTIVE: Schizophrenia affects about 1% of the general population and is a highly disabling
disease. Additionally, the rate of alcohol dependency for patients with schizophrenia is very
high. There are no established treatments for alcohol dependency and negative symptoms in
schizophrenia. This study will examine whether the addition of glycine to neuroleptic
medications will help patients with schizophrenia and alcoholism decrease their drinking as
well as improve negative symptoms.
RESEARCH PLAN: An abnormality of the glutamate neurotransmitter system has been hypothesized
for both alcoholism and schizophrenia. Studies suggest that the amino acid glycine may
improve alcohol dependency and symptoms of schizophrenia by acting on the N methyl D
aspartate (NMDA) glutamate receptor. Glycine causes reversal of the effects of ethanol in
animal studies and improves mood, social withdrawal and other so called "negative symptoms"
of schizophrenia. Consequently, the use of glycine by patients with schizophrenia and alcohol
dependency may potentially decrease alcohol craving and alcohol consumption and also improve
certain symptoms of schizophrenia. The potential of glycine to improve both alcohol
dependency and negative symptoms could represent an important step in the improvement of the
quality of life for patients with schizophrenia.
METHODOLOGY/FINDINGS/RESULTS: In order to test this hypothesis, we will use a double blind,
placebo controlled study and measure the number of drinks, the degree of craving for alcohol
and symptoms of schizophrenia among other parameters. Our principal approach to analyses of
medication effectiveness will be the application of the linear mixed effect model. The linear
mixed effect model permits a flexible approach for studying change in individuals through
time as a random effect, and does not require all patients to have data at all measured
points. Our principal model of analysis includes treatment (placebo or glycine), as between
subject factor, and time, as within subject factor. Compliance will be also included as a
time varying independent variable. This project continues to recruit subjects.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
| Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
| Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
| Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
| Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
| Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
| Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
| Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
| Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
| Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
| Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
| Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
| Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
| Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |